An Introduction to Thyroid Disorders
Thyroid disorders encompass primary thyroid disease (hypothyroidism, thyrotoxicosis, thyroid enlargement), thyroid cancer and thyroid disease in pregnancy. Hypothyroidism is a highly prevalent global health problem. It can be successfully managed by lifelong treatment with levothyroxine, but challenges include underdiagnosis, optimal treatment of subclinical hypothyroidism, and the use of levothyroxine monotherapy versus combination with triiodothyronine. Thyroid cancer advances include therapies targeting the MAPK and PI3K/AKT/mTOR pathways, or VEGF, and have resulted in significant clinical benefits. Immunotherapies also appear promising. However, improved options are needed for patients with radioiodine-refractory differentiated thyroid cancer and undifferentiated cancers.
Browse our gallery of video highlights and short articles from the conference hub, providing the latest expert insights from major conferences and peer-reviewed articles from the journal portfolio.
Our supporting partners do not constitute an endorsement of the content on this page.
Thyroid Disorders Content
Coexistence of Thyrolipomatosis and Tongue Squamous Cell Carcinoma: A Case Report
touchREVIEWS in Endocrinology. 2023;19(1):Online ahead of journal publication
Thyrolipomatosis is a rare condition defined as a diffuse non-neoplastic infiltration of fatty tissue in the thyroid gland.1 Although fatty infiltration is common in other glands (e.g. salivary glands, parathyroids, thymus and pancreas), it is rare in the thyroid gland.2 If present, it is most frequently nodular (i.e. thyrolipoma) rather than diffuse (i.e. thyrolipomatosis).3 Thus, since the first […]
Glenn Braunstein: Research highlights from 2022
We were delighted to speak with our editorial board member Prof. Glenn Braunstein (Cedars-Sinai Medical Center, Los Angeles, CA, USA) around this year’s research highlights in thyroid disorders and what to look out for in 2023. Questions What are the key clinical highlights from 2022 in the field of thyroid disorders? (0:14) What are the […]
Kristien Boelaert, ATA 2022: The EGRET study: Long term mortality and cardiometabolic effects of hyperthyroidism treatment
Current evidence indicates cardio‐metabolic effects from antithyroid drugs and other definitive treatment options for hyperthyroidism. The EGRET study aimed to assess the differences in mortality and cardiometabolic outcomes depending on the method of treatment in order to better inform patient‐clinician decision‐making. In this touchENDOCRINOLOGY interview, Prof. Kristien Boelaert (University of Birmingham, Birmingham, United Kingdom) discusses […]
Kristien Boelaert, ATA 2022: Challenges of the long term treatment of hyperthyroidism
Hyperthyroidism, also called overactive thyroid, occurs when your thyroid gland overproduces thyroid hormones. In this touchENDOCRINOLOGY interview, Prof. Kristien Boelaert (University of Birmingham, Birmingham, United Kingdom) discusses the challenges faced in the long term treatment of hyperthyroidism. The abstract entitled: ‘LONG‐TERM MORTALITY AND CARDIOMETABOLIC EFFECTS OF TREATMENT FOR HYPERTHYROIDISM: EGRET STUDY‘ was presented at the American […]
Thyroid Function During and After COVID-19 Infection: A Review
touchREVIEWS in Endocrinology. 2022;18(1):58–62 DOI: https://doi.org/10.17925/EE.2022.18.1.58
On 31 December 2019, the World Health Organization (WHO) was notified of several cases of pneumonia of unknown aetiology in Wuhan, China. After a relatively short period, officials confirmed the first case of coronavirus disease 2019 (COVID-19) reported outside of China, in Thailand, on 13 January 2020.1 From the start of the pandemic to 11 November […]
Personalized treatment of RET-altered thyroid cancers: What is the value of biomarker testing and targeted therapies?
Leading experts explain the value of biomarker testing and targeted therapies for the personalized treatment of RET-altered thyroid cancers
- Distinguish between different types of thyroid cancers and describe therapies that are appropriate for their management
- Plan a personalized approach to treatment of RET-altered thyroid cancers, including use of biomarker testing and novel targeted therapies
- Evaluate the clinical trial data for novel targeted therapies for RET-altered thyroid cancers and apply it to clinical practice
Presentation of Pseudohypoparathyroidism Type 1b with Albright Hereditary Osteodystrophy and Laryngospasm: Case Report
US Endocrinology. 2021;17(1):Online ahead of journal publication
The clinical presentation of hypocalcemia varies based on the degree and chronicity of the derangement. Although many patients remain asymptomatic, mild symptoms of hypocalcemia include circumoral and extremity paresthesia, Chvostek’s sign and Trousseau’s sign; more severe derangements can present with cardiac arrythmias and seizures.1–3 Chronic hypocalcemia may present with cataracts and basal ganglia calcifications.2,3 Due […]
Ferdy van Geest, ETA 2021: Efficacy of T3 analogue Triac for MCT8 deficiency
Dr Ferdy van Geest, (Erasmus Medical Center, Rotterdam, The Netherlands) kindly spoke with us about the results of his study investigating Triac in patients with MCT8. The abstract entitled ‘Long-term efficacy of triiodothyronine analogue Triac in children and adults with monocarboxylate transporter 8 deficiency: an international, real-life cohort study’ (Abstract 82) was given at European […]
Lisanne de Koster, ETA 2021: FDG-PET/CT Prior to Diagnostic Thyroid Surgery
We caught up with Dr Lisanne de Koster, (Radboud University Medical Center, Nijmegen, The Netherlands) to discuss her study which investigated whether the use of FDG-PET/CT could prevent unnecessary diagnostic thyroid surgery. The abstract ‘Efficacy of 18F-FDG-PET/CT in evaluation of cytological indeterminate thyroid nodules prior to surgery (EfFECTS): a randomised-controlled multicentre trial’ (Abstract 49) was […]
Journal articles and more to your inbox
Get the latest clinical insights from touchENDOCRINOLOGYSign me up!